Company intelligence / Profile preview
Cytocraft Biopharmaceutical
Sichuan Sheng, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Cytocraft Biopharmaceutical is conducting Phase 1 clinical trials on assets including an autologous CAR-T targeting CD276 (B7-H3) for colorectal cancer and immune cell therapies for non-small cell lung cancer. Clinical data for lead programs are not yet published or public.
- Therapeutic areas
- Oncology
- Modalities
- Autologous CAR-TImmune cell therapyFusion proteinT-lymphocyte cell therapyBiological products
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
The First Affiliated Hospital of Zhengzhou University
Beyond the preview
Go deeper on Cytocraft Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytocraft Biopharmaceutical.